| Novavax is rising $1.21, or 11.5 percent, to $11.70, after the Los Angeles biopharmaceutical firm reported positive results of a phase III trial of Estrasorb, its experimental treatment for vasomotor symptoms, or hot flashes, in postmenopausal women. The company said that patients using Estrasorb in the randomized, double-blind trial experienced an 85 percent reduction in the total number of hot flashes during the course of the trial. Novavax also said that about half of the patients reported complete cessation of hot flashes during a 7-day period by week 10 of the treatment. Fewer than 10 percent of the patients in the placebo group noticed a similar improvement. |
